| 01/25 | Zymeworks Announces Participation in Upcoming Investor Conferences | BU |
| 01/20 | Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas.. | AQ |
| 01/04 | Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 | BU |
| 2022 | Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part.. | AQ |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conference | BU |
| 2022 | Zymeworks Announces Positive Topline Data in The Pivotal HERIZON-BTC-01 Trial Of Zanida.. | AQ |
| 2022 | Zymeworks Inc. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical.. | BU |
| 2022 | Zymeworks Inc - New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cance.. | AQ |
| 2022 | New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Toda.. | BU |
| 2022 | Zymeworks to Transfer Stock Listing to Nasdaq | BU |
| 2022 | Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab Lice.. | BU |
| 2022 | Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto.. | AQ |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conference | BU |
| 2022 | Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto.. | BU |
| 2022 | Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results | BU |
| 2022 | Zymeworks Bc Inc. : Entry into a Material Definitive Agreement, Termination of a Material .. | AQ |
| 2022 | Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and.. | BU |
| 2022 | Zymeworks Bc Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, .. | AQ |
| 2022 | Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab | BU |
| 2022 | Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and .. | AQ |
| 2022 | Zymeworks to Host Third Quarter Results Conference Call | BU |
| 2022 | Zymeworks Bc Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other.. | AQ |
| 2022 | Zymeworks Completes Plan to Become Delaware Corporation | BU |
| 2022 | Zymeworks Inc. : Entry into a Material Definitive Agreement, Termination of a Material Def.. | AQ |
| 2022 | Zymeworks : REPORT OF VOTING RESULTS - Form 8-K | PU |
| 2022 | Zymeworks Inc. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclo.. | AQ |
| 2022 | Zymeworks Announces Results of Special Meeting | AQ |
| 2022 | Zymeworks Announces Results of Special Meeting | BU |
| 2022 | Zymeworks Reminds Shareholders to Vote FOR its Redomicile | BU |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research a.. | AQ |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &.. | BU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile | BU |
| 2022 | Zymeworks : Shareholder Director Nominations - Form 8-K | PU |
| 2022 | Zymeworks Inc. : Other Events (form 8-K) | AQ |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR .. | BU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at.. | BU |
| 2022 | Zymeworks Inc. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve .. | BU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin.. | AQ |
| 2022 | Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin.. | BU |
| 2022 | Zymeworks Inc. : Other Events (form 8-K) | AQ |
| 2022 | Zymeworks Inc. : Unregistered Sale of Equity Securities (form 8-K) | AQ |
| 2022 | Zymeworks Inc. : Entry into a Material Definitive Agreement, Financial Statements and Exhi.. | AQ |
| 2022 | Zymeworks Inc. : Other Events (form 8-K) | AQ |
| 2022 | Zymeworks : FORM 51-102F3 - Form 8-K | PU |
| 2022 | Zymeworks Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, Fina.. | AQ |
| 2022 | Zymeworks : Provides Corporate Update andReports Second Quarter 2022 Financial Results - F.. | PU |
| 2022 | Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results | BU |
| 2022 | ZYMEWORKS INC. Management's Discussion and Analysis of Financial Condition and Results.. | AQ |
| 2022 | Zymeworks : Announces Participation in Upcoming Investor Conferences - Form 8-K | PU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conferences | BU |
| 2022 | Zymeworks : Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodoti.. | PU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Reports Inducement Grant To New Chief Scientific Officer | AQ |
| 2022 | Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodot.. | BU |
| 2022 | Zymeworks : Reports Inducement Grant to New Chief Scientific Officer - Form 8-K | PU |
| 2022 | Zymeworks Reports Inducement Grant to New Chief Scientific Officer | BU |
| 2022 | Zymeworks : to Host Second Quarter Results Conference Call - Form 8-K | PU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks to Host Second Quarter Results Conference Call | BU |
| 2022 | Zymeworks Announces Plan To Become A Delaware Corporation | AQ |
| 2022 | Zymeworks Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Oth.. | AQ |
| 2022 | Zymeworks Announces Plan to Become a Delaware Corporation | BU |
| 2022 | Zymeworks : Appoints Dr. Paul Moore as Chief Scientific Officer - Form 8-K | PU |
| 2022 | Zymeworks Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer | BU |
| 2022 | Zymeworks : Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to .. | PU |
| 2022 | Zymeworks Inc. : Entry into a Material Definitive Agreement, Material Modification to Righ.. | AQ |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
